TB-500

TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4 (Tβ4), a 43-amino-acid protein present in virtually all mammalian cells. It plays a central role in actin regulation, cell migration, and tissue repair. TB-500 is widely researched for its systemic healing properties — particularly for tendon, ligament, muscle, and cardiac tissue — and is notable for its ability to reduce scar tissue formation while simultaneously accelerating recovery. Its high molecular weight differentiates its mechanism from smaller peptides like BPC-157, and the two are frequently combined in research protocols for complementary healing coverage.

The core mechanism of TB-500 centers on its ability to sequester G-actin (globular actin monomers), regulating the actin cytoskeleton — the structural scaffold inside every cell. By binding actin, TB-500 promotes cell migration, proliferation, and differentiation, which are critical for wound closure and tissue remodeling. It significantly upregulates actin, cell division kinase 5 (CDK5), and PINCH protein expression. TB-500 also promotes angiogenesis by upregulating VEGF receptors and activating the PI3K/AKT pathway, increasing new vessel formation in ischemic tissue. Importantly, it modulates matrix metalloproteinase (MMP) activity to reduce excessive fibrosis and scar formation, making it particularly valuable in cardiac and soft-tissue research. TB-500 also exhibits potent anti-inflammatory properties by downregulating inflammatory cytokines including TNF-α and IL-1β.

TB-500 research encompasses cardiac repair, soft-tissue healing, and anti-fibrotic applications. Studies at Yale School of Medicine demonstrated Thymosin Beta-4 promotion of epicardial cell migration and cardiac progenitor activation after myocardial infarction. Phase I/II clinical trials (RegeneRx) in patients with STEMI found it safe with signals of improved cardiac function. Independent rodent studies confirm faster Achilles tendon healing, reduced scar tissue formation in muscle injuries, and improved cardiac remodeling post-MI. In vitro studies demonstrate TB-500 upregulates actin and PINCH proteins, with >400 peer-reviewed papers documenting Thymosin Beta-4 biology.

Injury Recovery Protocol (combined with BPC-157): TB-500 2.5 mg twice weekly + BPC-157 500 mcg daily subcutaneous for 6–8 weeks — considered the gold standard combination in soft-tissue injury research. Cardiac Health Protocol: TB-500 5 mg weekly alone or combined with Epithalon for cardiovascular repair research. Standalone Maintenance Protocol: 2 mg every 10–14 days indefinitely for general recovery support and systemic tissue maintenance.

TB-500 is generally well tolerated. The most frequently reported side effect is a temporary flu-like feeling — mild fatigue, slight fever, or general malaise — particularly during the loading phase when dosing is most frequent. This is thought to be an immune-modulatory response and usually resolves within 1–2 days. Mild headaches have been reported by some users. Injection site reactions including redness and swelling are possible but uncommon. There is theoretical concern about TB-500's pro-angiogenic properties in individuals with pre-existing malignancies, as VEGF upregulation could theoretically support tumor vascularity — this is a standard precautionary note in peptide research. No significant endocrine suppression has been documented.

Lyophilized TB-500 powder should be stored at -20°C (freezer) for long-term storage (up to 24 months) or at 2–8°C (refrigerator) for short-term storage up to 3 months. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Do not freeze reconstituted solution. Protect from light and heat at all times. TB-500 is typically supplied in 2 mg or 5 mg vials.